米氮平合并喹硫平治疗难治性抑郁症对照分析  

A comparative study of mirtazapine combining with quetiapine in the treatment of refractory depression

作　　者：刘珊[1] 吕江玲[1] 王圣海[1] 

机构地区：[1]山东省青岛市精神卫生中心,266034

出　　处：《精神医学杂志》2012年第4期274-276,共3页Journal of Psychiatry

摘　　要：目的观察米氮平合并喹硫平治疗难治性抑郁症的疗效。方法将41例难治性抑郁症患者随机分为研究组(米氮平合并喹硫平)21例和对照组(单用米氮平)20例,疗程8周。于治疗前及治疗后1、2、4、8周末分别以汉密尔顿抑郁量表(HAMD)、不良反应量表(TESS)评估疗效与安全性。结果治疗结束后,两组HAMD评分较治疗前显著降低(P<0.05),治疗后第2、4、8周末,研究组的HAMD评分显著低于对照组,差异有显著性意义(P<0.05)。研究组、对照组的有效率分别为90.5%、60.0%,两组之间疗效有显著性差异(P<0.05)。两组副作用均较少。结论米氮平合并喹硫平对难治性抑郁症的疗效更佳,优于单用米氮平。Objective To investigate the clinical efficacy of mirtazapine combining with quetiapine in the treatment of refractory depression. Methods A total of 41 patients with refractory depression were randomly divided into study group （21 cases） treated with mirtazapine combining with quetiapine and control group （20 cases） treated with mirtazapine for 8 weeks. The efficacy and side effects were evaluated with Hamilton Depression Rating Scale （HAMD） and Treatment Emergent Symptom Scale （TESS） at the baseline and the 1st, 2nd, 4th, 8th weekend. Results Scores of HAMD in two groups both decreased significantly （ P 〈 0.05 ） after the treatment. Scores of HAMD in study group were significantly lower than that in control group at the 2nd, 4th and 8th weekend （P 〈 0.05 ）. There was significant difference in effective power between study group and control group （90.5% vs. 60.0% , P 〈 0.05 ）. The side effects in the two groups were mild. Conclusion Mirtazapine combining with quetiapine has satisfactory tolerability and has better efficacy than mirtazapine monotherapy in the treatment of refractory depression

关 键 词：米氮平 喹硫平 难治性抑郁症 

分 类 号：R749.4[医药卫生—神经病学与精神病学]